Literature DB >> 24310455

Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.

Ahmet Kasim Kilic1, Asli Tuncer Kurne, Kader Karli Oguz, Figen Soylemezoglu, Rana Karabudak.   

Abstract

AIM: In demyelinating disease spectrum, tumor-like (tumefactive) demyelinating lesions (TDL) are rarely seen. Atypical imaging and clinical features of these lesions may cause misdiagnosis of tumor or abscess.
MATERIAL AND METHODS: 25 patients with TDL in our center were followed and clinical, magnetic resonance imaging (MRI), magnetic resonance spectroscopy, cerebrospinal fluid (CSF) findings and disease course were retrospectively evaluated.
RESULTS: Mean age at symptom onset was 29 years. Motor and sensory deficits were most common symptoms and 18 of them were polysymptomatic. Mostly frontal and parietal regions were affected. 10/25 patients were initially misdiagnosed clinically as brain abscess, primary central nervous system tumor metastasis. T2-hypointense rim, incomplete ring enhancement of the lesions on post-gadolinium T1- weighted imaging on brain MRI enabled accurate diagnosis of TDLs. 13 of 21 patients with first-TDL presentation sustained a monophasic course, remaining 8 patients converted to multiple sclerosis (MS) at a mean 38.4 months follow-up. Clinical isolated syndrome (CIS) patients were older than patients who developed MS and Expanded Disability Status Scale was lower (0.96 vs 3.7).
CONCLUSION: Although MRI, CSF and pathologic examination help in differential diagnosis of the mass lesions, close follow-up is still crucial for the definite diagnosis. A higher MS conversion rate was found in patients with a younger TDL onset age.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24310455     DOI: 10.5137/1019-5149.JTN.7690-12.3

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  9 in total

1.  Tumefactive multiple sclerosis presenting with tonic-clonic seizure.

Authors:  Amrou Ali Idris; Tahmina Begum; Kenneth Rowland Verlage; Mashrafi Ahmed
Journal:  BMJ Case Rep       Date:  2016-04-26

2.  Contralateral recurrence of tumefactive demyelination.

Authors:  Mohammed Nazir Khan; Mihail Guranda; Marco Essig
Journal:  Neuroradiol J       Date:  2015-10-01

3.  The Spectrum of Clinical Presentation of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Young Patients of Our Community.

Authors:  Hikmatullah K Sherani; Mohammad Hasan; Hassan Mumtaz
Journal:  Cureus       Date:  2021-11-14

4.  Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.

Authors:  Matthew A Tremblay; Javier E Villanueva-Meyer; Soonmee Cha; Tarik Tihan; Jeffrey M Gelfand
Journal:  J Neurol Sci       Date:  2017-08-10       Impact factor: 3.181

5.  Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System.

Authors: 
Journal:  Chin Med J (Engl)       Date:  2017-08-05       Impact factor: 2.628

6.  When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.

Authors:  Breanna Taylor; Mallika P Patel; Katherine B Peters
Journal:  CNS Oncol       Date:  2021-01-15

Review 7.  A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.

Authors:  Renata Conforti; Raffaella Capasso; Rosario Galasso; Mario Cirillo; Gemma Taglialatela; Luigi Galasso
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

8.  Progression of tumefactive demyelinating lesion in a child demonstrated with MRI.

Authors:  Marta De Simone; Barbara Brogna; Daniele Litterio Spitaleri; Giulio Cicarelli; Roberta Fantozzi; Bruno Guida
Journal:  Radiol Case Rep       Date:  2017-12-08

9.  Left Deep Frontal Cavernous Angioma Mimicking a Glioma in an Adult Patient.

Authors:  Andrea Boschi; Arturo Consoli; Annamaria Buccoliero; Giovanni Barbagli; Salvatore Mangiafico; Franco Ammannati
Journal:  Asian J Neurosurg       Date:  2018 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.